Short burst of radiation before Immuno-Chemo may boost esophageal cancer response
NCT ID NCT07678580
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study tests whether a short course of radiation followed by the immunotherapy drug tislelizumab plus chemotherapy can improve outcomes for people with a type of esophageal cancer that can be surgically removed. About 50 participants will receive either a low or high dose of radiation, then three cycles of tislelizumab and chemo, followed by surgery. The main goal is to see how many patients have no cancer cells left in the removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tislelizumab, albumin-bound paclitaxel, carboplatin, and short-course radiotherapy
What this could lead to
If successful, this approach could increase the chance of eliminating all cancer before surgery, potentially improving long-term outcomes for people with esophageal cancer.
What could go wrong
This is an early Phase 2 study with only 50 participants, so results may not apply broadly. Side effects from the combination of radiation, immunotherapy, and chemotherapy could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tangdu Hospital, Fourth Military Medical University
Xi'an, Shaanxi, 710038, China
Contact Phone: •••-•••-•••• Email: •••••@•••••